Exagen Inc. Common Stock

XGN

Exagen Inc. (XGN) is a biotechnology company focused on developing and commercializing diagnostic tests to improve the management of autoimmune diseases. The company specializes in innovative testing solutions that aid in diagnosing conditions such as lupus and rheumatoid arthritis, aiming to enhance patient outcomes through precise and early detection.

$7.27 +0.07 (0.97%)
🚫 Exagen Inc. Common Stock does not pay dividends

Company News

Exagen Inc. to Participate in Fourth Quarter Investor Conferences
GlobeNewswire Inc. • Ryan Douglas • November 11, 2025

Exagen Inc., a leading autoimmune diagnostics company, announced participation in two upcoming investor conferences in November 2025, highlighting its commitment to showcasing its innovative autoimmune testing solutions.

Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
Zacks Investment Research • Zacks Equity Research • June 13, 2024

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

BTIG Maintains Buy Rating for Exagen: Here's What You Need To Know
Benzinga • Benzinga Insights • March 22, 2023

BTIG has decided to maintain its Buy rating of Exagen (NASDAQ:XGN) and lower its price target from $6.00 to $5.00. Shares of Exagen are trading down 3.91% over the last 24 hours, at $2.21 per share. A move to $5.00 would account for a 126.24% increase from the current share price. About Exagen Exagen Inc is a commercial-stage diagnostics company ...

Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript
The Motley Fool • [email protected] (Motley Fool Transcribing) • August 5, 2022

XGN earnings call for the period ending June 30, 2022.

Related Companies